This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: D35.2 (benign neoplasm of pituitary gland) | Special Copayment Reduction: V162 (severe intractable disease, 5 years) |
| B. Synonyms | Pituitary adenoma, pituitary tumor, benign pituitary tumor, pituitary microadenoma, pituitary macroadenoma |
| C. Adult onset | Possibility of adult onset Very high — pituitary adenoma occurs at all ages but is most frequent in the 30s to 60s, and is mainly diagnosed in adulthood by clinical symptoms due to hormone hypersecretion (acromegaly, Cushing disease, prolactinoma) and mass effect (visual field defect, headache). |
| 1. History | Late 19th century: Harvey Cushing pioneers pituitary surgery → early 20th century: hormone secretion characteristics elucidated → 1970s: transsphenoidal surgery standardized → molecular pathology and 2022 WHO classification revision. |
| 2. Causes | Monoclonal somatic mutations (GNAS, USP8, DICER1, etc.), MEN1 and CDKN1B germline mutations; sporadic variants account for most; radiation exposure is a rare cause. |
| 3. Genetics | Mutations of the MEN1 gene (11q13), AIP gene (11q13.3), CDKN1B (p27), PRKAR1A, and GNAS (20q13.32); associated with MEN1, FIPA, and Carney complex. |
| 4. General epidemiology | Prevalence of asymptomatic adenoma about 14.4% in autopsy studies; prevalence of clinically diagnosed adenoma about 77-94/100,000; prolactinoma is the most common at 40-50% of the total. |
| 5. Pathophysiology | Monoclonal proliferation → abnormalities in cell cycle regulatory pathways such as cAMP/PKA, Rb, Wnt, and Notch → hormone hypersecretion and mass effect. |
| 6. Symptoms | Symptoms of hormone hypersecretion (acromegaly, Cushing syndrome, amenorrhea-galactorrhea, thyrotoxicosis), mass effect (headache, visual field defect), hypopituitarism. |
| 7. Signs | Bitemporal hemianopia, optic disc pallor, Cushingoid signs (moon face, purple striae, central obesity), signs of acromegaly (enlargement of the hands, feet, and mandible; voice change). |
| 8. Screening | Regular screening of those with a family history of MEN1 or AIP; hormone screening tests when associated symptoms such as diabetes, hypertension, infertility, or hypogonadism are present. |
| 9. Diagnosis | Serum hormone tests (GH/IGF-1, PRL, ACTH, 24-hour urinary free cortisol, dexamethasone suppression test), pituitary MRI (gadolinium contrast enhancement), visual field testing. |
| 10. Treatment | Transsphenoidal surgery (TSS), dopamine agonists (cabergoline and bromocriptine, first-line treatment for prolactinoma), somatostatin analogues (octreotide), radiosurgery (Gamma Knife), growth hormone receptor antagonist (pegvisomant). |
| 11. Prognosis | Postoperative remission rate 85-95% for microadenomas and 50-80% for macroadenomas; prolactinoma can be controlled in about 80-90% with dopamine agonists; recurrence rate 10-20%. |
| 12. Prevention | Early detection through regular screening tests in those with a family history of hereditary syndromes (MEN1, AIP variants); most are sporadic, so primary prevention is not possible. |
| 13. References | Melmed S et al. Nat Rev Dis Primers. 2022 and 9 other papers |
Clinical recognition of pituitary tumors dates back to the late 19th century. In 1886, Pierre Marie described that acromegaly is associated with specific bodily changes, and the following year Oscar Minkowski proposed an association between this condition and pituitary enlargement. However, the most important figure in the history of pituitary surgery is the American neurosurgeon Harvey Cushing (1869-1939). In the early 20th century, Cushing systematized the clinical symptoms of pituitary tumors and in 1912 established pituitary surgery using a transcranial approach. In 1932 he first described Cushing's disease caused by an ACTH-secreting pituitary tumor.
The relationship between hormone secretory function and tumor type gradually became clear in the mid-20th century. With the development of radioimmunoassay (RIA) in the 1950s, quantitative measurement of serum growth hormone, prolactin, ACTH, and others became possible, and the functional classification of pituitary adenomas was established. In the 1970s, Jules Hardy standardized the surgical microscope and the transsphenoidal approach, laying the foundation for pituitary microsurgery. This method is still used as the standard surgical approach for pituitary adenomas.
Histological classification has evolved over decades. The traditional classification by chromophilia on hematoxylin-eosin staining (acidophil, basophil, chromophobe) shifted, with the introduction of immunohistochemistry (1970s-80s), to a functional classification according to expression of GH, PRL, ACTH, FSH, LH, TSH, and alpha subunit. The 2004 WHO classification introduced the concept of atypical adenoma, but it was abolished in the 2017 WHO classification. In the latest 2022 WHO classification of endocrine tumors, the nomenclature of pituitary neoplasms was changed to 'pituitary neuroendocrine tumor (PitNET),' and a new lineage-based classification system was introduced. This subdivides tumors according to transcription factor expression (Pit-1, T-PIT, SF-1) into the Pit-1 lineage (somatotroph, lactotroph, and thyrotroph tumors), the T-PIT lineage (corticotroph tumors), and the SF-1 lineage (gonadotroph tumors).
The history of treatment has also advanced continuously. The introduction of bromocriptine (a dopamine agonist) in the 1970s made medical treatment of prolactinoma possible, and in the 1990s cabergoline was introduced as a more effective dopamine agonist. Somatostatin analogues (octreotide, 1988; lanreotide) greatly improved the medical treatment of acromegaly. In 1997, the growth hormone receptor antagonist pegvisomant was developed and added to the treatment of acromegaly resistant to somatostatin analogues. Since the 2000s, endoscopic transsphenoidal surgery has rapidly spread as an alternative to microscopic surgery, and radiosurgical techniques such as Gamma Knife radiosurgery and proton beam therapy have also advanced.
The cause of pituitary adenoma (PitNET) is in most cases a monoclonal somatic mutation originating in a single cell, progressing through a multistep carcinogenesis process. About 95% or more of all cases are sporadic, and about 5% are associated with hereditary syndromes.
GNAS gene mutations are found in about 40% of growth hormone-secreting adenomas (GH-cell tumors). GNAS encodes the Gsα protein, and when a mutation (Arg201His, Arg201Cys, etc.) occurs, GTPase activity is lost, cAMP remains persistently elevated, and cell proliferation and GH secretion are promoted. USP8 gene mutations are the most common somatic mutation, found in about 35-62% of ACTH-secreting adenomas (Cushing's disease). USP8 is a deubiquitinating enzyme, and when mutated, recycling of the EGF receptor (EGFR) increases, promoting proliferation of ACTH-secreting cells. DICER1 variants have been reported in a small number of pituitary tumors and may be related to DICER1 syndrome (associated with pleuropulmonary blastoma, etc.).
Loss of function of the tumor suppressor genes retinoblastoma gene (RB1) and abnormalities of CDKN2A (p16/p14ARF) and others have been identified in some adenomas. Increased Rb phosphorylation due to cyclin D1 (CCND1) overexpression and CDK4/6 activation promotes the G1→S transition of the cell cycle. Tumors with high proliferation markers (Ki-67 proliferation index, etc.) may show aggressive behavior.
Chronic stimulation by hypothalamic regulatory signals such as growth hormone-releasing hormone (GHRH), corticotropin-releasing hormone (CRH), and dopamine can promote adenoma development. In GHRH-secreting neuroendocrine tumors (MEN1, etc.), acromegaly is caused by ectopic GHRH. Multiple endocrine neoplasia (MEN) syndromes and ergot alkaloid exposure may raise the risk of tumor development through pituitary stimulation.
About 5% of all pituitary adenomas are associated with a hereditary predisposition. In multiple endocrine neoplasia type 1 (MEN1), germline mutations of the MEN1 gene (tumor suppressor gene, 11q13) cause pituitary adenomas (mainly prolactinoma and GH-secreting tumors). In familial isolated pituitary adenoma (FIPA), AIP (aryl hydrocarbon receptor interacting protein) gene variants are found in about 15-30%. In MEN4 (MEN1-like phenotype), CDKN1B (p27Kip1) variants have been identified. In Carney complex, PRKAR1A (17q24.2) variants cause GH-secreting adenomas.
The genetics of pituitary adenoma is divided into sporadic and hereditary forms, each showing characteristic molecular abnormalities.
Germline mutations of the MEN1 gene (11q13, tumor suppressor gene, encoding the menin protein) cause MEN1 syndrome. In MEN1, pituitary adenomas occur in about 40-65% of patients, with prolactinoma (40%), GH-secreting tumors (25%), and nonfunctioning adenomas predominating. Menin has several functions, including acting as a transcriptional corepressor, regulating DNA repair, and regulating the Rb pathway. Children of MEN1 patients have a 50% chance of inheriting the mutation, so when a confirmed case occurs in a family, germline genetic testing and regular screening are recommended.
Germline variants of the AIP (aryl hydrocarbon receptor interacting protein) gene (11q13.3) are found in about 15-30% of patients with familial isolated pituitary adenoma (FIPA). AIP variants are associated especially with young age at onset (often before age 30), large tumors, and GH- or PRL-secreting adenomas. The AIP protein interacts with the aryl hydrocarbon receptor (AHR) and is involved in regulating cell proliferation and cAMP signaling. Carriers of AIP variants may have a lower treatment response to somatostatin analogues.
The CDKN1B gene (p27Kip1, 12p13.1) is a cell cycle inhibitor, and germline variants cause MEN4 syndrome with accompanying pituitary adenoma (including ACTH-secreting tumors). CDKN1B testing is considered in patients who show the clinical MEN1 phenotype but have no MEN1 gene variant.
Carney complex, caused by germline variants of the PRKAR1A gene (17q24.2, protein kinase A regulatory subunit 1α), causes somatotroph hyperplasia and GH-secreting adenoma together with cutaneous myxomas, spotty skin pigmentation, and multiple endocrine tumors. Loss of PRKAR1A induces cell proliferation through PKA overactivation.
GNAS (Gsα, 20q13.32) somatic mutations (R201H/C, Q227L/R) occur in about 35-40% of sporadic GH-secreting adenomas, and GNAS-mutant tumors have high expression of somatostatin receptor type 2 (SSTR2) and a relatively good response to somatostatin analogue treatment. USP8 mutations (14q32.2, ACTH-secreting adenoma) show a female predominance, and the tumors are often small.
CDKN2A (p16) promoter hypermethylation, histone modifications such as H3K27me3, and abnormal expression of specific miRNAs (miR-26a, miR-128, etc.) are known to be involved in pituitary adenoma development, which explains the epigenetic mechanism of sporadic tumor development.
Pituitary adenoma (PitNET) is the third most common intracranial tumor after meningioma and glioma and accounts for most benign pituitary neoplasms. Prevalence estimates differ greatly depending on the study method (autopsy, imaging, clinical registry).
Autopsy studies: In several autopsy studies that systematically examined pituitary tissue, the prevalence of asymptomatic microadenoma was reported as about 14.4% (range 1.5-27%). This means that a considerable proportion of the entire population harbors asymptomatic microadenomas. Clinical prevalence: In the Belgian study by Daly et al. (2006), the prevalence of clinically diagnosed pituitary adenoma was reported as about 77-94/100,000, far higher than previous estimates. Similar ranges have been reported in recent UK national registry data. Incidence: The annual incidence is estimated at about 4/100,000 and is continuing to increase as 'incidentalomas' are discovered more often owing to the widespread use of MRI.
Prolactinoma accounts for about 40-50% of all pituitary adenomas and is the most common clinically diagnosed type. It is 5-10 times more common in women than in men (especially women in their 20s to 40s), with an incidence of about 5-17/100,000 in women and about 1-2/100,000 in men. Nonfunctioning adenomas are most common in older age (40s to 60s), with a male-to-female ratio that is similar or slightly higher in men. They account for about 25-30% of all adenomas. The prevalence of GH-secreting adenoma (acromegaly) is about 40-70 per million, and the annual incidence is 3-4 per million. The prevalence of ACTH-secreting adenoma (Cushing's disease) is about 39 per million, and the annual incidence is 1-2 per million, with women outnumbering men 3-8 times.
Microadenomas with a maximum diameter of less than 10 mm account for about 60-70% of the total, and macroadenomas of 10 mm or more account for about 30-40%. Macroadenomas are more common among nonfunctioning adenomas, and GH- and ACTH-secreting adenomas tend to be found at a relatively small size.
Precise prevalence data in Korea are limited, but analysis of Health Insurance Review & Assessment Service (HIRA) data shows that the number of patients with pituitary adenoma is continuing to increase. In Korea as well, the increase in incidentally discovered adenomas due to wider MRI availability is an issue, and diagnostic and treatment guidelines follow international standards.
The pathophysiology of pituitary adenoma begins with monoclonal proliferation of a single pituitary cell. This progresses through a multistep process involving cell cycle regulation abnormalities, activation of signaling pathways, and changes in the tumor microenvironment.
X-chromosome inactivation analysis and molecular marker studies have confirmed that pituitary adenomas are monoclonal proliferations of single-cell origin. Initial triggering events include activating mutations of GNAS (Gsα) (GH-cell tumors), USP8 mutations (ACTH-cell tumors), and loss of the AIP gene. cAMP accumulation due to GNAS mutation activates the transcription factor CREB via PKA, which induces GH secretion and proliferation of somatotroph cells.
Loss of function of tumor suppressors (RB1, CDKN2A/p16, CDKN1B/p27) and overexpression of cyclins (cyclin D1, E) disable the G1/S checkpoint and promote unlimited cell division. In particular, inactivation by Rb phosphorylation activates the E2F transcription factor and induces entry into S phase.
Wnt/β-catenin pathway: Nuclear accumulation of β-catenin and activation of target genes such as cyclin D1 and c-Myc promote cell proliferation. Notch signaling: Overexpression of Notch1 and Notch3 has been identified in pituitary adenomas. MAPK/ERK pathway: In some adenomas, BRAF (V600E) or Ras mutations activate the MAPK pathway and induce cell proliferation. PI3K/Akt/mTOR pathway: Decreased PTEN expression and PI3K/Akt activation have been reported in pituitary adenomas, contributing to cell survival and proliferation.
Transcription factors specific to each cell lineage (Pit-1, T-PIT, SF-1) are overexpressed in tumor cells and induce excessive hormone synthesis and secretion. In ACTH-cell tumors, transcription of the POMC (pro-opiomelanocortin) gene is overactivated by CRH and USP8 signaling, and in GH-cell tumors, GH synthesis is increased by GHRH receptor signaling and GNAS activating mutations.
Pituitary adenomas are richly vascularized, and angiogenesis due to VEGF overexpression sustains tumor growth. Immune cells such as tumor-associated macrophages (TAM) and regulatory T cells play an immunosuppressive role in the tumor microenvironment. Abnormal FGF receptor signaling has also been identified in some adenomas.
The clinical symptoms of pituitary adenoma are broadly classified into three categories: symptoms of hormone hypersecretion, hypopituitarism, and mass effect. Each type has a characteristic symptom pattern.
Women: The main symptoms are amenorrhea, oligomenorrhea, infertility due to anovulation, galactorrhea, decreased libido, and osteoporosis due to low estrogen. Because microadenomas are common, mass effect symptoms are not frequent. Men: Decreased libido, erectile dysfunction, infertility, gynecomastia, and (rarely) galactorrhea appear, and because men recognize symptoms late, the tumor is often a macroadenoma at diagnosis.
When it occurs in adults, acromegaly develops. It is accompanied by gradual enlargement of the hands, feet, and mandible, changes in facial appearance (frontal bossing, enlargement of the nose and lips), skin thickening and increased sweating, voice change (deepening), tongue enlargement (macroglossia), joint pain (articular cartilage hypertrophy), carpal tunnel syndrome, salivary gland enlargement, cardiac enlargement (cardiomyopathy), hypertension, diabetes mellitus, and sleep apnea. When it occurs in children and adolescents before the epiphyses close, gigantism appears. Because symptoms progress gradually, it takes an average of 7-10 years to reach diagnosis.
Cushing syndrome develops from cortisol excess caused by excessive ACTH secretion. Central obesity (abdomen, neck, face), moon face, buffalo hump, purple striae, skin atrophy and easy bruising, muscle weakness (especially proximal), hypertension, abnormal blood glucose, osteoporosis, depression/anxiety/cognitive impairment, amenorrhea, hirsutism, and susceptibility to infection due to immunosuppression appear.
Nonfunctioning adenomas present with mass effect without symptoms of hormone hypersecretion. Headache is the most common early symptom. Visual field defect: compression of the optic chiasm causes bitemporal hemianopia. Hypopituitarism causes sequential deficiency of growth hormone, gonadotropins, thyroid-stimulating hormone, and ACTH. Rarely, pituitary apoplexy (hemorrhage or infarction within the adenoma) causes sudden headache, visual loss, and decreased consciousness.
A very rare type (<1% of the total), it presents with symptoms of thyrotoxicosis due to thyroid overstimulation (tachycardia, sweating, weight loss, tremor, goiter without ocular symptoms). Central hyperthyroidism, with elevated serum T3 and T4 and a normal or elevated TSH, is characteristic.
Physical signs of pituitary adenoma differ according to the type of hormone hypersecretion and the mass effect.
Bitemporal hemianopia is the classic sign of optic chiasm compression and appears in large macroadenomas. On fundus examination, optic disc pallor is a sign of chronic optic nerve compression. When the ocular motor nerves (cranial nerves 3, 4, and 6) are involved, diplopia and ptosis occur (with cavernous sinus involvement).
Enlargement of the hands and feet (increased ring and shoe size), anterior protrusion of the mandible (prognathism), increased interdental spacing, frontal bossing, enlargement of the nasal bridge, enlargement of the lips and tongue, skin thickening and hyperhidrosis, acrochordons (skin fibromas), and deepening of the voice are characteristic. Joint crepitus and joint pain accompany it.
Moon face, multiple acne, fat deposition in the neck and trunk (buffalo hump, supraclavicular fat pads), abdominal purple striae (>1 cm wide), proximal muscle weakness (difficulty rising from a chair), skin atrophy and purpura, generalized edema, and signs of hypertension are identified on physical examination.
When hypopituitarism accompanies it, pale skin, bradycardia, hypotension, loss of pubic and axillary hair, orthostatic hypotension (when ACTH is low), hypothermia, hypoglycemia (with combined GH and ACTH deficiency), and growth retardation (in children) are observed.
Sudden severe headache ("thunderclap headache"), nausea and vomiting, visual loss, ocular motility disorder, and decreased consciousness develop acutely. Signs of meningeal irritation (neck stiffness) may accompany it.
On MRI it appears as a low-signal (T1) or high-signal (T2) lesion within the pituitary, and after gadolinium contrast the tumor shows relatively delayed enhancement compared with the normal pituitary. In macroadenomas, superior extension above the optic chiasm, lateral invasion of the cavernous sinus (Knosp grade), and inferior invasion of the sphenoid sinus are identified.
Screening of the entire general population for pituitary adenoma is not performed because of low cost-effectiveness. However, systematic screening for early detection is important in certain high-risk groups.
MEN1 syndrome confirmed or suspected patients and first-degree relatives: measurement of serum PRL, IGF-1, and other pituitary hormones and pituitary MRI are performed at intervals of every 1-3 years starting from age 10-15 or from the time of confirmation. AIP variant carriers: screening for growth hormone excess or pituitary lesions is performed from adolescence in family members carrying the AIP gene variant. Carney complex: regular pituitary hormone screening and, when necessary, MRI are performed in PRKAR1A variant carriers.
In patients with characteristic symptoms, the corresponding hormone tests are performed first. Women with amenorrhea and galactorrhea: measure serum PRL. Infertility or hypogonadism: measure FSH, LH, PRL, and testosterone (men)/estrogen (women). Adults with poorly controlled diabetes or hypertension: measure IGF-1 (screening for acromegaly). Clinical suspicion of Cushing syndrome (combination of obesity, diabetes, hypertension, and osteoporosis): 1 mg overnight dexamethasone suppression test or 24-hour urinary free cortisol. Visual field defect or headache: pituitary MRI first.
A pituitary incidentaloma found on head MRI/CT performed for headache, trauma, or another purpose requires systematic evaluation. Screening of all pituitary hormones (PRL, IGF-1, GH, ACTH, 24h UFC or LNSC, TSH, free T4, LH, FSH, sex hormones) and visual field testing for lesions of 8 mm or larger or contact with the optic chiasm are recommended.
Diagnosis of pituitary adenoma combines biochemical hormone tests and imaging, and is completed by postoperative pathological confirmation.
Prolactinoma: Serum PRL > 200 μg/L is almost specific for macroprolactinoma. 100-200 μg/L suggests prolactinoma or the stalk effect, and at <100 μg/L other causes (medications, hypothyroidism, etc.) must be excluded. Dilution testing is needed to avoid the "hook effect" (immunoassays reporting falsely low values at very high PRL). Acromegaly: Elevated serum IGF-1 is the most reliable screening test. Failure of GH suppression on the 75 g oral glucose tolerance test (OGTT) (GH persistently ≥ 1 μg/L) is the criterion for confirmation. Cushing's disease: After Cushing syndrome is confirmed by the 1 mg overnight dexamethasone suppression test (serum cortisol >50 nmol/L), elevated 24-hour urinary free cortisol (UFC), and elevated midnight salivary cortisol, the pituitary cause is confirmed by elevated ACTH (ACTH-dependent), the 8 mg high-dose dexamethasone suppression test (50% or greater suppression in Cushing's disease), and bilateral inferior petrosal sinus sampling (IPSS).
Pituitary MRI (gadolinium-enhanced dynamic study) is the standard imaging test. Microadenomas (< 10 mm) show delayed enhancement compared with the normal pituitary on dynamic contrast-enhanced studies and appear as low signal. For macroadenomas, size, involvement of surrounding structures (cavernous sinus, optic chiasm), and the degree of superior extension are evaluated. When there is no lesion or the lesion is ambiguous on MRI, central ACTH hypersecretion is confirmed by IPSS (inferior petrosal sinus sampling).
In resected tissue after surgery, expression of GH, PRL, ACTH, FSH, LH, TSH, alpha subunit, and transcription factors (Pit-1, T-PIT, SF-1) is confirmed by immunohistochemistry. The Ki-67 proliferation index and p53 expression are used to predict invasiveness and recurrence risk. The lineage-based classification according to the 2022 WHO classification is included in the final pathology report.
Treatment of pituitary adenoma applies one or a combination of surgery, medication, and radiotherapy according to tumor type, size, presence of hormone hypersecretion, and patient condition.
It is the first-line treatment for most functioning adenomas (GH-, ACTH-, and TSH-secreting tumors) and for large nonfunctioning adenomas causing visual disturbance or hypopituitarism. Endoscopic transsphenoidal surgery (ETSS) is currently preferred because it allows a wider field of view and more complete resection than microscopic surgery. The remission rate is 85-95% for microadenomas and 50-80% for macroadenomas. Major complications include diabetes insipidus (1-20%), hypopituitarism, cerebrospinal fluid rhinorrhea, optic nerve injury, and meningitis.
Prolactinoma: Dopamine agonists (DA) are the first-line treatment. Cabergoline (0.25-2 mg twice weekly) is preferred because it is more effective and better tolerated than bromocriptine. The PRL normalization rate is about 80-90%, and tumor size reduction is about 70-80%. If the tumor has disappeared on MRI after 2-3 years of treatment, tapering or discontinuation of the dopamine agonist can be attempted. Acromegaly: Somatostatin receptor ligands (SRL: octreotide, lanreotide) normalize GH/IGF-1 levels in about 50-70%. The growth hormone receptor antagonist (pegvisomant) is used in SRL resistance or partial response, with an IGF-1 normalization rate of 90% or more. Adding cabergoline (combination therapy) provides additional benefit in some patients. Cushing's disease: When surgery fails or the disease recurs, steroidogenesis inhibitors (ketoconazole, metyrapone, osilodrostat) and pituitary-directed drugs (pasireotide, an SRL analogue; cabergoline) are used. Osilodrostat (Isturisa) is a new steroidogenesis inhibitor approved in 2020.
Gamma Knife, CyberKnife, or fractionated radiotherapy is performed for residual or recurrent tumors after surgery and in patients at high surgical risk. Normalization of hormones takes several years, and there is a risk of developing hypopituitarism (about 50% eventually).
Pituitary adenoma (PitNET) mostly follows a benign course, but prognosis varies according to tumor type, size, and invasiveness.
Prolactinoma: Long-term control is possible with dopamine agonists, and after 2-3 years or more of treatment, medication can be discontinued in some patients (about 30%) who remain in sustained remission. The recurrence rate after drug discontinuation is 30-50%. The risk of worsening of microadenomas during pregnancy is low. Acromegaly: When GH and IGF-1 are normalized after treatment, the excess mortality risk from cardiovascular and respiratory complications decreases, but when cardiomyopathy, diabetes, and joint damage due to delayed diagnosis have already occurred, complete recovery is difficult. The postoperative remission rate is 85-95% for microadenomas and 50-80% for macroadenomas. Cushing's disease: The postoperative remission rate is about 70-80% at experienced centers. The recurrence rate is about 15-20% within 10 years, and in case of recurrence, reoperation, radiotherapy, or adrenalectomy may be needed. Untreated Cushing's disease has high mortality because of increased cardiovascular risk, susceptibility to infection, and psychiatric complications. Nonfunctioning adenoma: Visual field recovery improves in most patients (70-80%) after surgery, but hypopituitarism may not recover even after surgery. The recurrence rate is about 20-40% within 5 years, requiring long-term follow-up. Invasive and recurrent adenomas: Invasive adenomas with cavernous sinus invasion, high Ki-67, and p53 positivity have a high risk of recurrence. Temozolomide is used in aggressive adenomas or pituitary carcinoma.
Primary prevention of sporadic pituitary adenoma is currently not possible. However, early detection and prevention of complications are important in carriers of hereditary syndromes.
Family screening for hereditary syndromes: In family members carrying MEN1 or AIP variants, regular hormone testing and pituitary MRI are performed from adolescence for early detection when the tumor is small. Prevention of complications of hormone hypersecretion: Early diagnosis and treatment can prevent cardiomyopathy, diabetes, and joint damage in acromegaly; osteoporosis, cardiovascular risk, and immunosuppression in Cushing's disease; and osteoporosis and infertility in prolactinoma. Prevention of pituitary apoplexy: In patients with macroadenomas, be aware of and cautious about the risk of apoplexy with the use of anticoagulants or antiplatelet agents, severe hypotension, trauma, and dynamic hormone stimulation testing. Minimizing radiation exposure: Because cranial radiotherapy raises the risk of hypopituitarism and, rarely, secondary pituitary tumors, cranial radiation exposure is minimized except when necessary. Long-term follow-up: Regular hormone tests and MRI follow-up are essential after treatment for early detection of recurrence and hypopituitarism.